Who makes JP-1366 and apixaban?

JP-1366 and apixaban is developed by Onconic Therapeutics Inc..

What development phase is JP-1366 and apixaban in?

JP-1366 and apixaban is in Phase 1.

Last reviewed 2026-05-14 · How we verify

JP-1366 and apixaban

Onconic Therapeutics Inc. · Phase 1 active Small molecule

At a glance

Generic name	JP-1366 and apixaban
Sponsor	Onconic Therapeutics Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

JP-1366 and apixaban CI brief — competitive landscape report
JP-1366 and apixaban updates RSS · CI watch RSS
Onconic Therapeutics Inc. portfolio CI